Musacchio A, Martínez G, Alvarez L, Guerra I, Acosta N, Amador Y, Pérez A, Soria Y, Puentes P, Dueñas S

Language: English
References: 14
Page: 180-182
PDF size: 181.42 Kb.

Text Extraction

The incomplete definition of immunologic parameters that correlates with the protection against HCV infection has limited the development of a vaccine against this pathogen. Several studies advocate for the induction of strong cellular immune response against viral antigens, as well as neutralizing antibodies against HCV E2 envelope protein, as a success criteria. However, the influence of several antigens against each others in a protein preparation and the impact on the immunogenicity, have not been explored yet. In the present study a factorial design was used to generate several HCV vaccine preparations with the structural core, E1 and E2 proteins as antigens. An optimal antigen composition was chosen based on the lymphoproliferative response against HCV as well as protection against challenge with a surrogate virus in BALBC/c mice. The protein ratio (1:160:160), with 0.1 µg of Co.120-16.7 µg of E1.340-16.7 µ g E2.680 (Co-E1-E2) was selected as the optimal composition to induce a functional immune response in mice. Additionally, strong humoral immune response against the 412-438 amino acid region from HCV E2 protein was detected when African green monkeys were immunized with Co-E1-E2. This region includes a conserved epitope, involved in T cell lymphoproliferative response against Co.120 and E2.680 proteins as well as in HCV neutralization. The results evidenced the relevance of proportion between HCV structural antigens in vaccine preparations for eliciting successful immune response.

REFERENCES

1. Caruntu FA, Benea L. Acute hepatitis C virus infection: Diagnosis, pathogenesis, treatment. J Gastrointestin Liver Dis. 2006; 15:249-56.

2. Veldt BJ, Saracco G, Boyer N, Cammà C, Bellobuono A, Hopf U, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut. 2004; 53:1504-8.

3. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature. 2005;436:961-6.

4. Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, Zachoval R, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology. 1999; 117:933-41.

5. Houghton M, Choo QL, Chien D, Kuo G, Weiner A, Coates S, et al. Development of an HCV vaccine. In: Rizzetto M, Purcell RH, Gerin JL, Verme G, editors. Viral hepatitis and liver diseases. Turín: Minerva Medica; 1997. p. 656-9.

6. Li P, Wan Q, Feng Y, Liu M, Wu J, Chen X, et al. Engineering of N-glycosylation of hepatitis C virus envelope protein E2 enhances T cell responses for DNA immunization. Vaccine. 2007;25:1544-51.

7. Puig M, Major ME, Mihalik K, Feinstone SM. Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine. 2004;22:991-1000.

8. Martinez-Donato G, Acosta-Rivero N, Morales-Grillo J, Musacchio A, Vina A, Alvarez C, et al. Expression and processing of hepatitis C virus structural proteins in Pichia pastoris yeast. Biochem Biophys Res Commun. 2006;342:625-31.

9. Acosta-Rivero N, Poutou J, Alvarez-Lajonchere L, Guerra I, Aguilera Y, Musacchio A, et al. Recombinant in vitro assembled hepatitis C virus core particles induce strong specific immunity enhanced by formulation with an oil-based adjuvant. Biol Res. 2009;42:41-56.

10. Musacchio A, Duenas-Carrera S, Alvarez-Lajonchere L, Acosta-Rivero N, Martinez-Donato G, Guirola M, et al., inventors; Center for Genetic Engineering and Biotechnology, asignee. Vaccine composition against hepatitis c virus. International patent WO2006024240. 2006 Mar 9.

11. Krishnadas DK, Ahn JS, Han J, Kumar R, Agrawal B. Immunomodulation by hepatitis C virus-derived proteins: targeting human dendritic cells by multiple mechanisms. Int Immunol. 2010;22:491-502.

12. Martínez-Donato G, Musacchio A, Alvarez-Lajonchere L, Acosta-Rivero N, Amador Y, Guerra I, et al. Ratio of HCV structural antigens in protein-based vaccine formulations is critical for functional immune response induction. Biotechnol Appl Biochem. 2010;56:111-8.

13. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ and Liang TJ. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci USA. 2003;100:6753-8.

14. Zhang P, Wu CG, Mihalik K, Virata-Theimer ML, Yu MY, Alter HJ, et al. Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci USA. 2007;104:8449-54.